Sabby Management, LLC Cel Sci Corp Transaction History

Sabby Management, LLC

$9.65 Million
Q4 2024

A detailed history of Sabby Management, LLC transactions in Cel Sci Corp stock. As of the latest transaction made, Sabby Management, LLC holds 711,735 shares of CVM stock, worth $291,811. This represents 2.94% of its overall portfolio holdings.

Number of Shares

711,735

Holding current value

$291,811

% of portfolio

2.94%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$0.4 - $1.11 $284,694 - $790,025	711,735 New	711,735 $284,000
Q3 2021 Nov 15, 2021	SELL	$7.64 - $12.49 $1.11 Million - $1.81 Million	-145,285 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$8.68 - $27.49 $1.26 Million - $3.99 Million	145,285 New	145,285 $1.26 Million
Q1 2021 May 17, 2021	SELL	$12.0 - $27.64 $3.72 Million - $8.57 Million	-310,155 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$11.05 - $16.62 $2.24 Million - $3.36 Million	202,277 Added 187.51%	310,155 $3.62 Million
Q3 2020 Nov 16, 2020	BUY	$11.69 - $14.54 $227,499 - $282,962	19,461 Added 22.01%	107,878 $1.38 Million
Q2 2020 Aug 14, 2020	BUY	$9.75 - $17.6 $325,474 - $587,523	33,382 Added 60.66%	88,417 $1.32 Million
Q1 2020 May 15, 2020	BUY	$7.54 - $17.05 $414,963 - $938,346	55,035 New	55,035 $635,000
Q1 2019 May 15, 2019	SELL	$2.58 - $3.54 $83,220 - $114,186	-32,256 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$2.65 - $4.26 $19,716 - $31,694	7,440 Added 29.98%	32,256 $93,000
Q3 2018 Nov 14, 2018	BUY	$0.83 - $4.16 $6,826 - $34,216	8,225 Added 49.58%	24,816 $101,000
Q2 2018 Aug 14, 2018	BUY	$0.92 - $3.5 $15,263 - $58,068	16,591 New	16,591 $15,000
Q4 2017 Feb 14, 2018	SELL	$1.63 - $2.0 $958,149 - $1.18 Million	-587,822 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$1.59 - $3.0 $934,636 - $1.76 Million	587,822	587,822 $976,000

Others Institutions Holding CVM

# of Institutions

Shares Held

6.98M

Call Options Held

27.1K

Put Options Held

108K

View Full List

About CEL SCI CORP

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $17.8M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

More about CVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sabby Management, LLC with notifications on news.

Account